Voloridge Investment Management
SYRE icon

Voloridge Investment Management’s Spyre Therapeutics SYRE Stock Holding History

Voloridge Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-264,317
Closed -$4.43M – 1348
2025
Q3 		$4.43M Sell
264,317
-14,603
-5% -$238K 0.01% 777
2025
Q2 		$4.18M Buy
278,920
+21,488
+8% +$318K 0.02% 799
2025
Q1 		$4.15M Buy
257,432
+141,962
+123% +$2.95M 0.02% 834
2024
Q4 		$2.69M Sell
115,470
-41,011
-26% -$1.2M 0.01% 903
2024
Q3 		$4.6M Sell
156,481
-118,745
-43% -$3.31M 0.02% 798
2024
Q2 		$6.47M Buy
275,226
+87,173
+46% +$2.94M 0.02% 682
2024
Q1 		$7.13M Buy
+188,053
New +$5.45M 0.03% 565

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Voloridge Investment Management's SYRE Position: Q4 2025 in Review

Voloridge Investment Management sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 264,317 shares — an estimated $4.43M sold.

Voloridge Investment Management first reported a position in SYRE in Q1 2024 and held it in 7 quarters. The position peaked at $7.13M in Q1 2024. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Voloridge Investment Management reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 264,317 Spyre Therapeutics shares in Q4 2025, an estimated $4.43M.
  • Voloridge Investment Management first reported a position in Spyre Therapeutics in Q1 2024 and held it in 7 quarters.
  • Voloridge Investment Management's Spyre Therapeutics position peaked at $7.13M in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.